Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis
Abstract Background Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies in China and is an exceptionally drug-resistant tumor with a 5-year survival rate less than 15%. Cisplatin is the most commonly used conventional chemotherapeutic drug for the treatment of ESCC, but...
Main Authors: | Xinfang Yu, Wei Li, Zhenkun Xia, Li Xie, Xiaolong Ma, Qi Liang, Lijun Liu, Jian Wang, Xinmin Zhou, Yifeng Yang, Haidan Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-06-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-017-3442-y |
Similar Items
-
Definitive Chemoradiation with Concurrent Weekly Cisplatin in the Treatment of Esophageal Squamous Cell Carcinoma – A Simplistic Approach
by: Imtiaz Ahmed, et al.
Published: (2021-05-01) -
Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma
by: Xin Wang, et al.
Published: (2023-03-01) -
Pharmacological Inhibition of PP2A Overcomes Nab-Paclitaxel Resistance by Downregulating MCL1 in Esophageal Squamous Cell Carcinoma (ESCC)
by: Qi Song, et al.
Published: (2021-09-01) -
Molecular mechanism underlying epithelial‐mesenchymal transformation and cisplatin resistance in esophageal squamous cell carcinoma
by: Kewei Song, et al.
Published: (2023-11-01) -
PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
by: Jia Zhao, et al.
Published: (2023-12-01)